Kynurenine pathway

Also known as kynureninase deficiency, this extremely rare inherited disorder is caused by the defective enzyme kynureninase which leads to a block in the pathway from tryptophan to niacin (nicotinic acid). As a result, tryptophan is no longer a source of niacin, hence leading to pellagra (niacin deficiency). Both B₆-responsive and B₆-unresponsive forms are known. Patients with this disorder excrete excessive amounts of xanthurenic acid, kynurenic acid, 3-hydroxykynurenine, and kynurenine after tryptophan loading and are said to suffer from tachycardia, irregular breathing, arterial hypotension, cerebellar ataxia, developmental retardation, coma, renal tubular dysfunction, renal or metabolic acidosis, and even death. The only biochemical abnormality noted in affected patients was a massive hyperkynureninuria, seen only during periods of coma or after intravenous protein loading. This disturbance was temporarily corrected by large doses of vitamin B₆. The activity of kynureninase in the liver was markedly reduced. The activity was appreciably restored by the addition of pyridoxal phosphate.[13][14][15][16]

Downregulation of kynurenine 3-monooxygenase (KMO) can be caused by genetic polymorphisms, cytokines, or both.[17][18] KMO deficiency leads to an accumulation of kynurenine and to a shift within the tryptophan metabolic pathway towards kynurenic acid and anthranilic acid.[19][20][21][22][23][24]

Deficiencies of one or more enzymes on the kynurenine pathway leads to an accumulation of intermediate metabolic products which can cause effects depending on their concentration, function and their inter-relation with other metabolic products.[19] For example, kynurenine 3-monooxygenase deficiency is associated with disorders of the brain (such as schizophrenia and tic disorders) and of the liver.[22][20][21][23][24] The mechanism behind this observation is typically a blockade or bottleneck situation at one or more enzymes on the kynurenine pathway due to the effects of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) and/or due to genetic polymorphisms afflicting the particular genes.[19][18][25][21] Dysfunctional states of distinct steps of the kynurenine pathway (such as kynurenine, kynurenic acid, quinolinic acid, anthranilic acid, 3-hydroxykynurenine) have been described for a number of disorders, for example:[26]

• HIV dementia
• Tourette syndrome
• Tic disorders
• Psychiatric disorders[5][6] (such as schizophrenia,[5][7] major depressive disorder,[8][5] bipolar disorder,[1][5][2][8] anxiety disorders)
• Multiple sclerosis
• Huntington's disease
• Encephalopathies
• Lipid metabolism
• Liver fat metabolism
• Systemic lupus erythematosus
• Glutaric aciduria
• Vitamin B₆ deficiency
• Eosinophilia-myalgia syndrome
• long COVID [27]

Scientists are investigating the role of dysregulation of this pathway in aging, neurodegenerative diseases, mental disorders, somatic symptom disorders, and chronic fatigue syndrome (CFS).[28][29][30][31][2][1]

Changes in the ratio of kynurenine versus tryptophan are reported for many diseases like arthritis, HIV/AIDS, neuropsychiatric disorders,[1][6][2] cancer and inflammations.[32][33][34][35] The kynurenin/tryptophan is also an indicator for the activity of indoleamine 2,3-dioxygenase (IDO).[36][37]